Study of IbrutNCT03112174inib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)

Official Title

Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma

Summary:

This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.

Trial Description

Primary Outcome:

• Occurrence of Tumour Lysis Syndrome (TLS)
• Occurrence of Dose Limiting Toxicities (DLT)
• Progression-free Survival (PFS)
• Complete Response (CR)

View this trial on ClinicalTrials.gov